Exhibit 99.1


                                                           FOR IMMEDIATE RELEASE


         Protein Polymer Technologies and Surgica Sign Option Agreement
                       to Acquire all of Surgica's Assets

      Agreement Accelerates Protein Polymer Technologies' Commercial Entry

San Diego, CA - November 28, 2005 - Protein Polymer Technologies, Inc. (OTC
Bulletin Board: PPTI.OB), a biotechnology device company that is a pioneer in
protein design and synthesis and Surgica Corporation today announced that they
have signed an Asset Purchase Option Agreement which, if the option is
exercised, would result in the acquisition of all of Surgica's assets by a
wholly-owned subsidiary of PPTI in exchange for PPTI common stock. The option
will become effective no later than December 17, 2005, subject to the
satisfaction of certain conditions, and upon the effective date, PPTI and
Surgica will enter into a License Agreement under which PPTI will acquire
exclusive rights to Surgica's technology and products. Currently, Surgica has
three Food and Drug Administration (FDA) cleared polyvinyl alcohol (PVA) based
embolization products - PVA Plus(TM), MicroStat(TM) and MaxiStat(TM), with
additional products in development. Surgica operates a FDA-registered facility
for manufacture of these medical devices.

"This agreement, together with the license and related agreements, represents a
significant milestone in our strategic plan to add shareholder value by
bolstering our product portfolio and pipeline with innovative therapies that
speed our entry into commercialization," said William N. Plamondon III, Chief
Executive Officer of Protein Polymer Technologies. "Surgica's embolization
products provide an important minimally invasive treatment option for patients
and will allow us to enter the growing embolization market."

Transaction Summary

Under the terms of the Option Agreement, PPTI will acquire a two-year option to
purchase substantially all of Surgica's assets for an initial common stock grant
of 2 million shares and a potential future incentive issuance of additional
common shares based on future sales performance of Surgica's products. Any
securities offered or issued in connection with the purchase of Surgica's assets
have not been registered under the Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration under such Act
or an applicable exemption from such registration requirements.

Under the terms of the License Agreement, PPTI will acquire the rights to the
three embolization products, one issued patent, and technical and market
know-how in return for the assumption of up to approximately $650,000 of certain
Surgica liabilities, cash payments of up to approximately $400,000 against
certain other Surgica liabilities and a royalty to Surgica of 25 percent of net
profits on revenues generated by the sale of the Surgica products.







A related Supply and Services Agreement provides for the manufacture of product
by Surgica and the provision of services to PPTI, including further product
development, in exchange for operating payments to Surgica.

The transaction was structured to enable both companies to begin working
together as quickly as possible in order to maximize sales growth for the
licensed products. When, and if, the Asset Purchase Option is exercised by PPTI,
Surgica would then operate as a division of PPTI and it is contemplated that
Louis R. Matson, Founder and Chief Executive Officer of Surgica, would assume
the role of division president, reporting to Mr. Plamondon. Until such time,
Surgica will continue to operate as an independent company with Mr. Matson
continuing in his current positions.

Key Product Highlights

Surgica's patented PVA foam embolization products are manufactured according to
a proprietary process, and include both spherical and standard particle forms.
Advancing standard PVA technology that has been safely used in humans for over
30-years, Surgica's products have fluid suspension properties intended to
maximize product performance. Currently, Surgica's products are cleared for use
in endovascular management of arteriovenous malformations (AVMs) and neoplastic
lesions when presurgical devascularization is desirable.

     o    PVA Plus(TM) - is used to embolize smaller blood vessels

     o    MaxiStat(TM) - is used to embolize medium blood vessels

     o    MicroStat(TM) - is used to embolize tumors

Surgica is also developing an additional product, Blocker(TM) that will be used
to embolize larger blood vessels.

Beyond Surgica's current indication for use, upon completion of the transaction,
PPTI intends to submit a new 510(k) application to the FDA to expand labeled
indications for Surgica's products to include treatment of uterine fibroids,
liver cancer and certain other applications. PPTI and Surgica also intend to
develop drug delivery applications based on the Surgica technology platform.

Market Potential

Primarily used by interventional radiologists, embolization products are used to
treat a variety of medical conditions by blocking blood flow to tissues, damaged
blood vessels, vascular malformations and tumors including uterine fibroids.

One of the most rapidly growing areas for embolization is the minimally invasive
treatment of uterine fibroids. Approximately 70 percent of the projected 275,000
hysterectomies performed to treat uterine fibroids in 2005 would benefit from
this procedure. The Company estimates a conservative annual market potential for
uterine fibroid embolization (UFE) could exceed $200 million in the U.S. and
$300 - $500 million worldwide.







Embolic agents are also used in the treatment of inoperable liver cancer, a
condition affecting approximately 75,000 people in the United States in 2005,
with an annual market potential of $200 million U.S. and $400 million worldwide.


About Protein Polymer Technologies, Inc.

Protein Polymer Technologies, Inc. is a biotechnology company that discovers and
develops innovative therapeutic devices to improve medical and surgical
outcomes. The Company focuses on developing technology and products to be used
for soft tissue augmentation, tissue adhesives and sealants, wound healing
support and drug delivery devices. Protein Polymer Technologies' proprietary
protein-based biomaterials are uniquely tailored to optimize clinical
performance and contain no human or animal components that could potentially
transmit or cause disease. The Company is headquartered in San Diego,
California. For additional information about the Company, please visit
www.ppti.com.

To date, PPTI has been issued twenty-six U.S. patents on its core technology
with corresponding issued and pending patents in key international markets.

This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially from
those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer to
the Company's 2004 Annual Report Form 10-KSB and 10KSB/A and other recent
filings with the Securities and Exchange Commission, copies of which are
available from the Company, to further ascertain the risks associated with the
above statements.

                                      # # #


Investor Contact:                                 Media Contact:
Erin Davis, (858) 558-6064 x 120                  Bryan deCastro, (631) 495-9177
Protein Polymer Technologies, Inc.                Carole Boucard, (954) 370-2524
                                                  Creative Public Relations